Benchmark Co. Remains a Buy on Humacyte (HUMA)
Humacyte to Participate at Upcoming Investor Conferences in September
Both Retail Investors Who Control a Good Portion of Humacyte, Inc. (NASDAQ:HUMA) Along With Institutions Must Be Dismayed After Last Week's 14% Decrease
Humacyte(HUMA.US) Officer Sells US$5.72 Million in Common Stock
Humacyte Reports Positive Results From ATEV Treatment of Vascular Trauma in Ukraine
Humacyte Presents Positive Long-Term Results of ATEV in Treatment of Vascular Trauma in Military Setting From Ukraine Humanitarian Program
Dr. Juliana Blum Joins BioAesthetics as CEO
How Is The Market Feeling About Humacyte?
Small Cap Stocks: FDA Delay Created Buy-On-The-Dip Opportunity for Humacyte (HUMA)
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
10-Q: Q2 2024 Earnings Report
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Earnings Call Summary | Humacyte(HUMA.US) Q2 2024 Earnings Conference
Express News | Humacyte Inc : Btig Cuts Target Price to $10 From $11
Express News | Humacyte Inc -Reported Cash and Cash Equivalents of $93.6 Million as of June 30, 2024
Express News | Humacyte Q2 Operating Expenses USD 29.499 Million
Express News | Humacyte Q2 Basic EPS USD -0.48
Express News | Humacyte Q2 Net Income USD -56.663 Million Vs. IBES Estimate USD -27.3 Million
Express News | Humacyte Inc Shares up 3.4% Premarket Ahead of Q2 Results After Falling 16.4% on Monday
Humacyte Second Quarter 2024 Financial Results and Business Update